(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 27 August 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®) will be shared during a 'best poster session' at the European Society of Cardiology (ESC) Congress in London, UK. The poster presentation, titled 'Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study' will be part of the 'Best posters in pulmonary hypertension treatment strategies' session with a focussed discussion with the lead author, Prof Dr Irene Lang...
↧